MC
MXCT icon

Moors & Cabot’s MaxCyte MXCT Stock Holding History

Moors & Cabot’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,708
Closed -$48.3K – 927
2025
Q1 		$48.3K Buy
17,708
+4,528
+34% +$17.9K ﹤0.01% 854
2024
Q4 		$54.8K Hold
13,180
– – ﹤0.01% 871
2024
Q3 		$51.3K Buy
13,180
+295
+2% +$1.24K ﹤0.01% 866
2024
Q2 		$50.5K Buy
12,885
+353
+3% +$1.52K ﹤0.01% 832
2024
Q1 		$52.5K Buy
+12,532
New +$58.8K ﹤0.01% 879
2023
Q3 		– Sell
-26,969
Closed -$124K – 863
2023
Q2 		$124K Buy
26,969
+15,600
+137% +$71.7K 0.01% 788
2023
Q1 		$56.3K Buy
+11,369
New +$56K ﹤0.01% 818

Other funds holding MXCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Moors & Cabot's MXCT Position: Q2 2025 in Review

Moors & Cabot sold out of MaxCyte (MXCT) in Q2 2025, closing a stake of 17,708 shares — an estimated $48.3K sold.

Moors & Cabot first reported a position in MXCT in Q1 2023 and held it in 7 quarters. The position peaked at $124K in Q2 2023. 120 funds tracked by Wall St. Rank hold MXCT as of Q2 2025.

  • Moors & Cabot reported no remaining MaxCyte position as of Q2 2025 after selling out during the quarter.
  • Moors & Cabot sold 17,708 MaxCyte shares in Q2 2025, an estimated $48.3K.
  • Moors & Cabot first reported a position in MaxCyte in Q1 2023 and held it in 7 quarters.
  • Moors & Cabot's MaxCyte position peaked at $124K in Q2 2023.
  • 120 funds tracked by Wall St. Rank held MaxCyte as of Q2 2025.

Based on Moors & Cabot's 13F filing for Q2 2025, filed 6 Aug 2025.